317 related articles for article (PubMed ID: 34092252)
1. Anti-peptidylarginine deiminase-4 antibodies at mucosal sites can activate peptidylarginine deiminase-4 enzyme activity in rheumatoid arthritis.
Demoruelle MK; Wang H; Davis RL; Visser A; Hoang J; Norris JM; Holers VM; Deane KD; Darrah E
Arthritis Res Ther; 2021 Jun; 23(1):163. PubMed ID: 34092252
[TBL] [Abstract][Full Text] [Related]
2. Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans.
Navarro-Millán I; Darrah E; Westfall AO; Mikuls TR; Reynolds RJ; Danila MI; Curtis JR; ; Rosen A; Bridges SL
Arthritis Res Ther; 2016 Oct; 18(1):241. PubMed ID: 27770831
[TBL] [Abstract][Full Text] [Related]
3. Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis.
Cappelli LC; Konig MF; Gelber AC; Bingham CO; Darrah E
Arthritis Res Ther; 2018 Mar; 20(1):59. PubMed ID: 29566742
[TBL] [Abstract][Full Text] [Related]
4. Serum antibodies to peptidylarginine deiminase-4 in rheumatoid arthritis associated-interstitial lung disease are associated with decreased lung fibrosis and improved survival.
Wilson TM; Solomon JJ; Humphries SM; Swigris JJ; Ahmed F; Wang H; Darrah E; Demoruelle MK
Am J Med Sci; 2023 Jun; 365(6):480-487. PubMed ID: 36918112
[TBL] [Abstract][Full Text] [Related]
5. Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis.
Darrah E; Giles JT; Davis RL; Naik P; Wang H; Konig MF; Cappelli LC; Bingham CO; Danoff SK; Andrade F
Front Immunol; 2018; 9():2696. PubMed ID: 30515171
[No Abstract] [Full Text] [Related]
6. Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease.
Giles JT; Darrah E; Danoff S; Johnson C; Andrade F; Rosen A; Bathon JM
PLoS One; 2014; 9(6):e98794. PubMed ID: 24901704
[TBL] [Abstract][Full Text] [Related]
7. Anti-protein arginine deiminase antibodies are distinctly associated with joint and lung involvement in rheumatoid arthritis.
Palterer B; Vitiello G; Del Carria M; D'Onofrio B; Martinez-Prat L; Mahler M; Cammelli D; Parronchi P
Rheumatology (Oxford); 2023 Jul; 62(7):2410-2417. PubMed ID: 36440916
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of anti-peptidylarginine deiminase type 4 antibodies in rheumatoid arthritis and unaffected first-degree relatives in indigenous North American Populations.
Ferucci ED; Darrah E; Smolik I; Choromanski TL; Robinson DB; Newkirk MM; Fritzler MJ; Rosen A; El-Gabalawy HS
J Rheumatol; 2013 Sep; 40(9):1523-8. PubMed ID: 23908443
[TBL] [Abstract][Full Text] [Related]
9. Relative efficiencies of peptidylarginine deiminase 2 and 4 in generating target sites for anti-citrullinated protein antibodies in fibrinogen, alpha-enolase and histone H3.
Damgaard D; Bawadekar M; Senolt L; Stensballe A; Shelef MA; Nielsen CH
PLoS One; 2018; 13(8):e0203214. PubMed ID: 30161253
[TBL] [Abstract][Full Text] [Related]
10. Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis.
Shi J; Darrah E; Sims GP; Mustelin T; Sampson K; Konig MF; Bingham CO; Rosen A; Andrade F
Ann Rheum Dis; 2018 Jan; 77(1):141-148. PubMed ID: 29070531
[TBL] [Abstract][Full Text] [Related]
11. Heavy Chain Constant Region Usage in Antibodies to Peptidylarginine Deiminase 4 as a Marker of Disease Subsets in Rheumatoid Arthritis.
Gómez-Bañuelos E; Shi J; Wang H; Danila MI; Bridges SL; Giles JT; Sims GP; Andrade F; Darrah E
Arthritis Rheumatol; 2022 Nov; 74(11):1746-1754. PubMed ID: 35675168
[TBL] [Abstract][Full Text] [Related]
12. Clinical and immunological aspects of anti-peptidylarginine deiminase type 4 (anti-PAD4) autoantibodies in rheumatoid arthritis.
Reyes-Castillo Z; Muñoz-Valle JF; Llamas-Covarrubias MA
Autoimmun Rev; 2018 Feb; 17(2):94-102. PubMed ID: 29196243
[TBL] [Abstract][Full Text] [Related]
13. Peptidylarginine Deiminase Autoimmunity and the Development of Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: The Hapten-Carrier Model.
Auger I; Balandraud N; Massy E; Hemon MF; Peen E; Arnoux F; Mariot C; Martin M; Lafforgue P; Busnel JM; Roudier J
Arthritis Rheumatol; 2020 Jun; 72(6):903-911. PubMed ID: 31820586
[TBL] [Abstract][Full Text] [Related]
14. Erosive rheumatoid arthritis is associated with antibodies that activate PAD4 by increasing calcium sensitivity.
Darrah E; Giles JT; Ols ML; Bull HG; Andrade F; Rosen A
Sci Transl Med; 2013 May; 5(186):186ra65. PubMed ID: 23698378
[TBL] [Abstract][Full Text] [Related]
15. High-Titer Rheumatoid Arthritis Antibodies Preferentially Bind Fibrinogen Citrullinated by Peptidylarginine Deiminase 4.
Blachère NE; Parveen S; Frank MO; Dill BD; Molina H; Orange DE
Arthritis Rheumatol; 2017 May; 69(5):986-995. PubMed ID: 28029744
[TBL] [Abstract][Full Text] [Related]
16. Anti-peptidyl-arginine deaminase 3 (PAD3) antibodies as a promising marker to measure joint damage in patients with rheumatoid arthritis.
Seaman A; Darrah E; Infantino M; Meacci F; Manfredi M; Benucci M; Mahler M
Autoimmun Rev; 2016 Jul; 15(7):776-80. PubMed ID: 26997641
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
[TBL] [Abstract][Full Text] [Related]
18. Macrophage extracellular traps require peptidylarginine deiminase 2 and 4 and are a source of citrullinated antigens bound by rheumatoid arthritis autoantibodies.
Bashar SJ; Holmes CL; Shelef MA
Front Immunol; 2024; 15():1167362. PubMed ID: 38476240
[TBL] [Abstract][Full Text] [Related]
19. Anti-PAD4 autoantibodies in rheumatoid arthritis: levels in serum over time and impact on PAD4 activity as measured with a small synthetic substrate.
Pollmann S; Stensland M; Halvorsen EH; Sollid LM; Kvien TK; Fleckenstein B; Molberg O
Rheumatol Int; 2012 May; 32(5):1271-6. PubMed ID: 21267570
[TBL] [Abstract][Full Text] [Related]
20. Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis.
Darrah E; Rosen A; Giles JT; Andrade F
Ann Rheum Dis; 2012 Jan; 71(1):92-8. PubMed ID: 21859690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
